Stifel Financial Corp Has $199,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS)

Stifel Financial Corp lowered its stake in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 75.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,673 shares of the biotechnology company's stock after selling 130,513 shares during the quarter. Stifel Financial Corp owned about 0.05% of Codexis worth $199,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CDXS. MetLife Investment Management LLC grew its position in shares of Codexis by 162.4% in the fourth quarter. MetLife Investment Management LLC now owns 46,160 shares of the biotechnology company's stock valued at $220,000 after purchasing an additional 28,569 shares during the last quarter. EAM Investors LLC bought a new stake in Codexis during the 4th quarter valued at approximately $869,000. Barclays PLC grew its holdings in Codexis by 14.2% in the 4th quarter. Barclays PLC now owns 237,176 shares of the biotechnology company's stock valued at $1,131,000 after buying an additional 29,548 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock worth $40,000 after buying an additional 3,783 shares during the period. Finally, CenterBook Partners LP acquired a new position in shares of Codexis during the fourth quarter worth approximately $4,688,000. Institutional investors and hedge funds own 78.54% of the company's stock.

Codexis Stock Down 4.5%

Shares of CDXS opened at $2.34 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The company has a 50-day simple moving average of $2.42 and a 200-day simple moving average of $3.71. Codexis, Inc. has a 52 week low of $1.90 and a 52 week high of $6.08. The firm has a market capitalization of $193.86 million, a P/E ratio of -2.69 and a beta of 2.56.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The firm had revenue of $7.54 million for the quarter, compared to the consensus estimate of $10.38 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. On average, equities research analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Codexis to a "sell" rating in a research note on Friday, May 16th.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.